Olga Kostrova /iStock via Getty Images All figures are in United States Dollars unless otherwise noted. G/T = grams per tonne (of gold or silver). GEOs = gold-equivalent ounces. SEOs = silver-equivalent ounces. AISC refers to all-in sustaining costs. LOMP = life of mine plan. TPD = tonnes per day. UG = Underground. MTPA = million tonnes per annum. FS/DFS = Definitive Feasibility Study. C&M = care ...
Olga Kostrova /iStock via Getty Images All figures are in United States Dollars unless otherwise noted. G/T = grams per tonne (of gold or silver). GEOs = gold-equivalent ounces. SEOs = silver-equivalent ounces. AISC refers to all-in sustaining costs. LOMP = life of mine plan. TPD = tonnes per day. UG = Underground. MTPA = million tonnes per annum. FS/DFS = Definitive Feasibility Study. C&M = care and maintenance. Financial figures are rounded to the nearest million for assets. Base case metal price assumptions referenced in the article are shown at the bottom of the article. Fair value estimates at multiple different gold/silver price sensitivities are also shown at the bottom of the update (bear case, base case, medium case, bull case, upper bull case). Introduction Franco-Nevada Corporation ( FNV ) sets the gold standard for quality and creating value for shareholders in the precious metals sector, benefiting from capital discipline, an incredible business model, and a nose for uncovering exceptional assets early. These attributes have allowed the company to deliver industry-leading total returns, amass the largest portfolio of royalties and streams within the sector at ~440 assets ( including 53 producing energy assets ), and deliver its 19th consecutive dividend increase earlier this year, bumping its dividend by 16% to US$0.44 ( $1.76 annualized ). The latter has given me a near 2.0% yield on cost from my cost basis of US$109.80 ( position started in December 2023 ). Franco-Nevada Buy Rating (Seeking Alpha Premium/PRO) However, with a very modest percentage of total free cash flow being paid out in dividends ( ~17% at spot prices ), there's arguably considerable room for future dividend growth, especially if Cobre Panama finds its way back online at some point, with the $2.0 billion in annual free cash flow ( current run rate ) entirely separate from this massive copper-gold-silver mine that's in preservation and safe management and the gold/silver deliveries i...
undefined undefined/iStock via Getty Images Jerome Powell’s Federal Reserve (“Fed”) has seemingly been through it all over the past few years. There was the COVID-19 pandemic followed by supply shortages, which ultimately sent inflation to its highest levels in recent memory. The inflation battle was then compounded by geopolitics: first, Russia’s invasion of Ukraine, then periodic uprisings betwe...
undefined undefined/iStock via Getty Images Jerome Powell’s Federal Reserve (“Fed”) has seemingly been through it all over the past few years. There was the COVID-19 pandemic followed by supply shortages, which ultimately sent inflation to its highest levels in recent memory. The inflation battle was then compounded by geopolitics: first, Russia’s invasion of Ukraine, then periodic uprisings between Israel and Iranian proxies. Powell, himself, has faced unprecedented political attacks from the current administration. In spite of the adversity, Powell’s Fed has helped rein in inflation to manageable levels. The work, however, has yet to accomplish the central goal of taming the headline to the 2% target. With Powell soon to depart, it doesn’t look like inflation will reach this target, especially with current affairs relating to developments in the Middle East. The conclusion of the Federal Open Market Committee’s (“FOMC”) two-day meeting on Wednesday reflected the challenge the Fed faces in combatting inflation in the face of all the negative externalities. Ahead of the March policy decision, U.S. equity markets have continued to slump , with indexes turning green here and there but mostly tracking in the red on an overall basis. YTD, the Dow Jones Industrial Average ( DJI ), the Nasdaq Composite ( NDX ), and S&P 500 ( SPY ) are all down 2.2%, 3.2%, and 1.9%, respectively. This also coincides with a decline in long-term Treasury yields to the roughly 4.18% mark. In my view, today’s rate decision wasn’t a surprise. Chairman Powell’s forward commentary also indicated that policymakers are likely to remain on course despite rising economic and geopolitical uncertainties. Here’s everything else you need to know about the March FOMC meeting. How Healthy Was The Labor Market Prior To The March FOMC Meeting? If there was one area flashing more concern heading into the March meeting, it was the labor market . February’s jobs report, for example, came in much worse than expe...
Richard Drury Today's market spotlight fell on consumer discretionary and healthcare sectors, where strong earnings beats, dividend hikes, and key regulatory approvals drove notable stock moves. Sectors of the day: Consumer Discretionary Macy’s ( M ) shares surged after the retailer reported fourth-quarter profits and fiscal 2026 sales guidance that exceeded Wall Street expectations, lifting senti...
Richard Drury Today's market spotlight fell on consumer discretionary and healthcare sectors, where strong earnings beats, dividend hikes, and key regulatory approvals drove notable stock moves. Sectors of the day: Consumer Discretionary Macy’s ( M ) shares surged after the retailer reported fourth-quarter profits and fiscal 2026 sales guidance that exceeded Wall Street expectations, lifting sentiment across the sector. Shares of peers Kohl’s ( KSS ) and Dillard’s ( DDS ) also climbed in sympathy with the upbeat results. Meanwhile, Williams-Sonoma ( WSM ) stock rose sharply after the premium kitchenware and home furnishings retailer delivered a Q4 profit beat and announced a double-digit dividend increase. Healthcare Johnson & Johnson ( JNJ ) shares gained as the company announced U.S. FDA approval for its once-daily pill Icotyde, co-developed with Protagonist Therapeutics ( PTGX ), to treat plaque psoriasis, a common autoimmune skin condition. Separately, the FDA issued draft guidance to support drug developers in using alternative methods instead of animal studies during early drug development stages, potentially accelerating innovation pipelines. More on markets Routine Vaccines Okay For Now: Investment Implications Of The Court Decision Retail Sector Recap: Consumers Pull Back On Weak Outlook Sector Rotation: Healthcare XLV Should Be The Next Stop Retail sales are forecast by the NRF to rise 4.4% in 2026 Macy's stock stands out as the only bargain among U.S. large-cap broadline retailers
Key Points REET carries a much lower expense ratio and greater assets under management than RWX. RWX delivered a stronger one-year return but lagged REET over five years on a total return basis. REET holds over 300 global real estate companies, offering broader diversification than RWX’s more concentrated ex-U.S. focus. 10 stocks we like better than SPDR Index Shares Funds - State Street SPDR Dow ...
Key Points REET carries a much lower expense ratio and greater assets under management than RWX. RWX delivered a stronger one-year return but lagged REET over five years on a total return basis. REET holds over 300 global real estate companies, offering broader diversification than RWX’s more concentrated ex-U.S. focus. 10 stocks we like better than SPDR Index Shares Funds - State Street SPDR Dow Jones International Real Estate ETF › The State Street SPDR Dow Jones International Real Estate ETF (NYSEMKT: RWX) focuses on international real estate outside the U.S, while the iShares Global REIT ETF (NYSEMKT: REET) offers global real estate exposure at a much lower cost and with broader diversification. Both RWX and REET target real estate equities, but their areas of focus are a bit different: RWX tracks international (ex-U.S.) property companies, whereas REET includes both U.S. and international real estate investment trusts and firms. This comparison looks at cost, performance, risk, and portfolio composition to help investors weigh which approach best aligns with their goals. Snapshot (cost & size) Metric RWX REET Issuer State Street iShares Expense ratio 0.59% 0.14% 1-yr return (as of March 16, 2026) 14.1% 6.9% Dividend yield 3.4% 3.4% Beta 0.90 1.07 AUM $310.5 million $4.8 billion Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. While the dividend yields for these ETFs are roughly the same, REET’s fees are notably lower, and it also manages a much larger pool of assets than RWX. Performance & risk comparison Metric RWX REET Max drawdown (5 y) -35.89% -32.06% Growth of $1,000 over 5 years $799 $996 What's inside REET provides exposure to over 300 global real estate firms across both U.S. and international markets. Its largest holdings include Welltower (NYSE:WELL) at 8.5%, Prologis (NYSE:PLD) at 7.2%, and Equinix (NASDAQ:EQIX) at 5.5%. The ...
The following companies are expected to report earnings prior to market open on 03/19/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Accenture plc (ACN)is reporting for the quarter ending February 28, 2026. The information technology services company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.86. This value represents a...
The following companies are expected to report earnings prior to market open on 03/19/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Accenture plc (ACN)is reporting for the quarter ending February 28, 2026. The information technology services company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.86. This value represents a 1.42% increase compared to the same quarter last year. ACN missed the consensus earnings per share in the 1st calendar quarter of 2025 by -0.7%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for ACN is 14.31 vs. an industry ratio of 14.60. Alibaba Group Holding Limited (BABA)is reporting for the quarter ending December 31, 2025. The internet company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.73. This value represents a 37.55% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2026 Price to Earnings ratio for BABA is 25.82 vs. an industry ratio of 17.50, implying that they will have a higher earnings growth than their competitors in the same industry. Darden Restaurants, Inc. (DRI)is reporting for the quarter ending February 28, 2026. The restaurant company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.95. This value represents a 5.36% increase compared to the same quarter last year. Zacks Investment Research reports that the 2026 Price to Earnings ratio for DRI is 19.29 vs. an industry ratio of 5.50, implying that they will have a higher earnings growth than their competitors in the same industry. Signet Jewelers Limited (SIG)is reporting for the quarter ending January 31, 2026. The jewelry retail company's consensus earnings per share forecast from the 2 analysts that follow the stock is $5.96. This value represents a 9.97% decrease compared to the same quarter last year. In the past year SIG has beat the expectations e...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking cl...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASN Ended 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the full year ended December 31, 2025, and provided business highlights. “2025 was a pivotal year for ProKidney, highlighted by positive Phase 2 REGEN-007 study results, alignment with the FDA on the accelerated approval pathway for rilparencel, and significant enrollment momentum in the Phase 3 PROACT 1 study,” said Bruce Culleton, M.D., CEO of ProKidney. “Looking ahead, we are well positioned to deliver on key upcoming milestones, including completion of enrollment for the Phase 3 PROACT 1 study this year followed by pivotal eGFR slope data in the second quarter of 2027. Our mission remains highly focused on bringing a potential new treatment option to patients with advanced CKD and diabetes at high risk of kidney failure – an area of high unmet medical need.” Key Accomplishments in 2025 Generated significant enrollment momentum in the Phase 3 PROACT 1 study, positioning the Company for a pivotal topline readout in Q2 2027 using eGFR slope. Confirmed with the U.S. Food and Drug Administration (FDA) in a July 2025 Type B meeting that eGFR slope in patients from the ongoing Phase 3 PROACT 1 study can serve as the surrogate en...
For a while, there were questions about whether or not artificial intelligence (AI) was pure hype or the next big thing. The answer largely depends on whom you ask, but one thing seems clear: AI tools have become a part of many people's daily lives and aren't going anywhere. It will inevitably evolve (like any other technology), but the broader shift is real. That said, there are plenty of AI comp...
For a while, there were questions about whether or not artificial intelligence (AI) was pure hype or the next big thing. The answer largely depends on whom you ask, but one thing seems clear: AI tools have become a part of many people's daily lives and aren't going anywhere. It will inevitably evolve (like any other technology), but the broader shift is real. That said, there are plenty of AI companies that likely won't stand the test of time. That's why if you're interested in investing in AI stocks, you should lean toward companies built to thrive regardless of how the technology develops. The following two companies fit that description and play very different roles in AI. 1. Taiwan Semiconductor Manufacturing Taiwan Semiconductor Manufacturing (TSM 1.85%), or TSMC for short, isn't a traditional AI stock in the sense that it has tools that can create recipes or workouts for you, or help you vibecode (create apps using natural language). However, it undoubtedly has one of the most important roles in AI. TSMC is a semiconductor foundry, meaning companies design their own chips and then take those designs to TSMC to actually make them. Apple uses them for iPhone chips, AMD uses them for processors, and Nvidia uses them for its graphics processing units (GPUs), just to name a few. It's the world's largest foundry by a considerable margin. Expand NYSE : TSM Taiwan Semiconductor Manufacturing Today's Change ( -1.85 %) $ -6.41 Current Price $ 339.57 Key Data Points Market Cap $1.8T Day's Range $ 339.33 - $ 347.95 52wk Range $ 134.25 - $ 390.20 Volume 12M Avg Vol 13M Gross Margin 58.73 % Dividend Yield 1.17 % For AI to function as we know it today, it relies on tons of physical hardware that acts as the brains of everything. This includes GPUs, central processing units (CPUs), and AI accelerators. Companies like Nvidia and AMD design many of these chips, but TSMC brings most of them to life. Many estimates indicate that its market share in the advanced AI chip industry i...
Never miss an episode. Follow The Big Take daily podcast today. The Federal Open Market Committee announced this afternoon that it would hold interest rates steady. The decision comes in spite of spiking oil prices and new market uncertainty driven by the Iran War. On today’s Big Take podcast, host David Gura sits down with Bloomberg Federal Reserve reporter Amara Omeokwe and Wharton professor and...
Never miss an episode. Follow The Big Take daily podcast today. The Federal Open Market Committee announced this afternoon that it would hold interest rates steady. The decision comes in spite of spiking oil prices and new market uncertainty driven by the Iran War. On today’s Big Take podcast, host David Gura sits down with Bloomberg Federal Reserve reporter Amara Omeokwe and Wharton professor and historian Peter Conti-Brown to discuss how the Fed is thinking about the Iran War and its impacts on the US economy — and what could shift its calculus in the months ahead. Read more: Fed to Hold Interest Rates Steady as Iran War Scrambles the Economic Outlook Listen and follow The Big Take on Apple Podcasts , Spotify or wherever you get your podcasts. Terminal clients: click here to subscribe. This episode was produced by: Julia Press; Editors: Tracey Samuelson; Fact-checker: Eleanor Harrison-Dengate; Sound Design/Engineer: Alex Sugiura; Senior Producer: Naomi Shavin; Senior Editor: Elisabeth Ponsot; Deputy Executive Producer: Julia Weaver; Executive Producer: Nicole Beemsterboer.
Oil prices are up -- way up. They've shot above $100 a barrel in some markets. Some analysts are predicting they will eventually hit $150 a barrel. Iran has said it intends to initiate actions that will send the price to $200. But what does that mean, exactly? Those prices are definitely higher than they were before the outbreak of the war in Iran, but do they represent "historic highs"? And what ...
Oil prices are up -- way up. They've shot above $100 a barrel in some markets. Some analysts are predicting they will eventually hit $150 a barrel. Iran has said it intends to initiate actions that will send the price to $200. But what does that mean, exactly? Those prices are definitely higher than they were before the outbreak of the war in Iran, but do they represent "historic highs"? And what do they mean for U.S. oil producers like ExxonMobil (XOM 0.78%) and Chevron (CVX +0.32%)? Prices, not price "The price of oil" isn't actually just a single number. Oil prices (plural) are determined by several factors, including what kind of oil you're talking about, where it comes from, where it's going, and when it's getting there. For example, the cost of a barrel of light sweet crude oil from the U.S.'s Permian Basin that's being sold in Texas today is very different from the price of a barrel of heavy sour crude from Venezuela that'll head for China next week. Generally speaking, the global benchmark oil price is Brent Crude, named for an international oil market based in the North Sea. The Brent Crude price is the per-barrel cost of the Intercontinental Exchange Brent Oil monthly futures contract for a blend of light sweet crude from the North Sea and Permian Basin, to be delivered in 1-2 months. That Brent Crude price governs about 80% of globally traded crude oil. The other major crude oil benchmark is West Texas Intermediate (WTI), which isn't for oil from a specific region, but rather for light sweet oil traded and delivered at Cushing, Oklahoma. However, there are dozens (if not hundreds) of other crude oil designations used around the world, including Murban Crude, the benchmark grade from Abu Dhabi, in the United Arab Emirates. Each of these has its own "spot price" (today's current trading price) and "futures price." Collectively, all of these are considered "oil prices." So are they at record highs or not? What's hot and what's not With tankers unable to move...
HJBC/iStock Editorial via Getty Images TotalEnergies ( TTE ) up 1% in Wednesday's trading as TD Cowen upgraded the French energy company to Buy from Hold with a $97 price target, raised from $80, citing peer-leading free cash flow growth, production growth, reserves/production, and rising return on capital employed. TD analyst Jason Gabelman said he had expected the market to discount Total's ( TT...
HJBC/iStock Editorial via Getty Images TotalEnergies ( TTE ) up 1% in Wednesday's trading as TD Cowen upgraded the French energy company to Buy from Hold with a $97 price target, raised from $80, citing peer-leading free cash flow growth, production growth, reserves/production, and rising return on capital employed. TD analyst Jason Gabelman said he had expected the market to discount Total's ( TTE ) strong suite of projects until it made it through trough free cash flow this year, but a November 2025 equity funded, gas-to-power deal accelerated that trough to 2025. Moreover, peer performance suggests investors have begun to value resource life more fully than in the recent past, perhaps as a result of plateauing U.S. shale production growth and decelerating non-OPEC growth, Gabelman said. TotalEnergies ( TTE ) should grow production by a 3% compound annual growth rate during 2025-30, the second strongest pace in the group, and generate the strongest FCF growth while continuing to lead the group in ROCE to 2030, the analyst said, estimating half of the company's $11B FCF growth to 2030 to occur in 2028-29. "The market was skeptical for some time that TTE would achieve 12% ROCE on the business, though demonstrated success and data center demand have derisked the business while introducing an opportunity for future growth in the 2030s," Gabelman wrote. More on TotalEnergies TotalEnergies: Then Came Iran TotalEnergies: LNG Exposure And AI Power Demand Offer Structural Growth TotalEnergies Q4 2025 Earnings Call Presentation
In trading on Wednesday, shares of the SHYD ETF (Symbol: SHYD) crossed below their 200 day moving average of $22.79, changing hands as low as $22.73 per share. SHYD shares are currently trading off about 0.5% on the day. The chart below shows the one year performance of SHYD shares, versus its 200 day moving average: Looking at the chart above, SHYD's low point in its 52 week range is $21.6803 per...
In trading on Wednesday, shares of the SHYD ETF (Symbol: SHYD) crossed below their 200 day moving average of $22.79, changing hands as low as $22.73 per share. SHYD shares are currently trading off about 0.5% on the day. The chart below shows the one year performance of SHYD shares, versus its 200 day moving average: Looking at the chart above, SHYD's low point in its 52 week range is $21.6803 per share, with $24.03 as the 52 week high point — that compares with a last trade of $22.75. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of the Innovator IBD 50 ETF (Symbol: FFTY) crossed below their 200 day moving average of $35.73, changing hands as low as $35.58 per share. Innovator IBD 50 shares are currently trading off about 2.5% on the day. The chart below shows the one year performance of FFTY shares, versus its 200 day moving average: Looking at the chart above, FFTY's low point in its 52 we...
In trading on Wednesday, shares of the Innovator IBD 50 ETF (Symbol: FFTY) crossed below their 200 day moving average of $35.73, changing hands as low as $35.58 per share. Innovator IBD 50 shares are currently trading off about 2.5% on the day. The chart below shows the one year performance of FFTY shares, versus its 200 day moving average: Looking at the chart above, FFTY's low point in its 52 week range is $22.91 per share, with $41.5035 as the 52 week high point — that compares with a last trade of $35.54. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of Skyline Champion Corp (Symbol: SKY) crossed below their 200 day moving average of $70.96, changing hands as low as $68.83 per share. Skyline Champion Corp shares are currently trading off about 7.1% on the day. The chart below shows the one year performance of SKY shares, versus its 200 day moving average: Looking at the chart above, SKY's low point in its 52 wee...
In trading on Wednesday, shares of Skyline Champion Corp (Symbol: SKY) crossed below their 200 day moving average of $70.96, changing hands as low as $68.83 per share. Skyline Champion Corp shares are currently trading off about 7.1% on the day. The chart below shows the one year performance of SKY shares, versus its 200 day moving average: Looking at the chart above, SKY's low point in its 52 week range is $52.12 per share, with $86.709 as the 52 week high point — that compares with a last trade of $72.40. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Tuesday, shares of the iShares MSCI USA Min Vol Factor ETF (Symbol: USMV) crossed below their 200 day moving average of $73.16, changing hands as low as $72.90 per share. iShares MSCI USA Min Vol Factor shares are currently trading off about 1.7% on the day. The chart below shows the one year performance of USMV shares, versus its 200 day moving average: Looking at the chart above, U...
In trading on Tuesday, shares of the iShares MSCI USA Min Vol Factor ETF (Symbol: USMV) crossed below their 200 day moving average of $73.16, changing hands as low as $72.90 per share. iShares MSCI USA Min Vol Factor shares are currently trading off about 1.7% on the day. The chart below shows the one year performance of USMV shares, versus its 200 day moving average: Looking at the chart above, USMV's low point in its 52 week range is $64.56 per share, with $76.13 as the 52 week high point — that compares with a last trade of $72.91. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of the Direxion Daily Healthcare Bull 3x Shares ETF (Symbol: CURE) crossed below their 200 day moving average of $94.42, changing hands as low as $92.28 per share. Direxion Daily Healthcare Bull 3x Shares shares are currently trading off about 5% on the day. The chart below shows the one year performance of CURE shares, versus its 200 day moving average: Looking at ...
In trading on Wednesday, shares of the Direxion Daily Healthcare Bull 3x Shares ETF (Symbol: CURE) crossed below their 200 day moving average of $94.42, changing hands as low as $92.28 per share. Direxion Daily Healthcare Bull 3x Shares shares are currently trading off about 5% on the day. The chart below shows the one year performance of CURE shares, versus its 200 day moving average: Looking at the chart above, CURE's low point in its 52 week range is $66 per share, with $123.80 as the 52 week high point — that compares with a last trade of $92.56. Click here to find out which 9 other ETFs recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Monday, shares of CNA Financial Corp (Symbol: CNA) crossed below their 200 day moving average of $47.30, changing hands as low as $47.25 per share. CNA Financial Corp shares are currently trading down about 1.2% on the day. The chart below shows the one year performance of CNA shares, versus its 200 day moving average: Looking at the chart above, CNA's low point in its 52 week range ...
In trading on Monday, shares of CNA Financial Corp (Symbol: CNA) crossed below their 200 day moving average of $47.30, changing hands as low as $47.25 per share. CNA Financial Corp shares are currently trading down about 1.2% on the day. The chart below shows the one year performance of CNA shares, versus its 200 day moving average: Looking at the chart above, CNA's low point in its 52 week range is $41.64 per share, with $52.36 as the 52 week high point — that compares with a last trade of $47.06. Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of CVS Health Corporation (Symbol: CVS) crossed below their 200 day moving average of $73.99, changing hands as low as $73.12 per share. CVS Health Corporation shares are currently trading off about 1.8% on the day. The chart below shows the one year performance of CVS shares, versus its 200 day moving average: Looking at the chart above, CVS's low point in its 52 w...
In trading on Wednesday, shares of CVS Health Corporation (Symbol: CVS) crossed below their 200 day moving average of $73.99, changing hands as low as $73.12 per share. CVS Health Corporation shares are currently trading off about 1.8% on the day. The chart below shows the one year performance of CVS shares, versus its 200 day moving average: Looking at the chart above, CVS's low point in its 52 week range is $58.35 per share, with $85.15 as the 52 week high point — that compares with a last trade of $73.39. The CVS DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.